Retrospective review of cataract surgery outcomes in Miniature Schnauzers

Miniature Schnauzers commonly develop both inherited and diabetic cataracts. Miniature Schnauzers also often present with concurrent metabolic disease at the time of cataract surgery. The purpose of this study was to evaluate cataract surgery outcomes in Miniature Schnauzers.

The Eye Care for Animals electronic medical record database (2012-2018) was searched for "phacoemulsification" and "Miniature Schnauzer." A minimum follow-up time of 1 year was required for inclusion in the study. Clinical history, pre- and postoperative bloodwork, postoperative treatments, and visual outcomes were reviewed in all cases.

Cataract surgery was performed on 67 patients and 124 eyes. 93.5% (116/124) of operated eyes were visual 1 year following cataract surgery. At the time of surgery, 79.1% were diabetic, 64.2% had hypercholesterolemia, 55.2% had hypertriglyceridemia, 16.4% had hyperadrenocorticism, and 9% had a history of pancreatitis. Dorzolamide was used postoperatively in 61.2% of patients, and its use was significantly associated with postoperative cholesterol levels above reference range. Lipemic aqueous occurred in 13.4% of patients.

Miniature Schnauzers presenting for cataract surgery are frequently affected by metabolic diseases and dyslipidemia; however, cataract surgery outcomes were not significantly affected during the study period. Dietary management, omega-3 fatty acid supplementation, and oral fibrates may reduce the incidence of lipemic aqueous in Miniature Schnauzers.